

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Xero Limited

ABN

160 661 183 (ARBN)

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- | | | |
|---|---|--|
| 1 | +Class of +securities issued or to be issued | (a) Fully paid ordinary shares in Xero Limited (Ordinary Shares)

(b) Conditional agreement to issue Ordinary Shares (Restricted Stock Units or RSUs)

(c) Unlisted options to subscribe for Ordinary Shares (Options) |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued | (a) 77,938 Ordinary Shares

(b) 377,925 RSUs

(c) 202,500 Options |

3 Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

(a) (i) 66,823 Ordinary Shares were issued in accordance with the Rules of the Xero Limited Employee Restricted Share Plan (**Share Plan**) as part of the remuneration package of employees based in Australia and the United Kingdom. Participating employees will become entitled to the Ordinary Shares in varying percentages over the period from 31 July 2019 to 31 March 2022, subject to the terms of the Share Plan, including the continued employment of the relevant employee with the Xero Limited Group on each vesting date.

(ii) 1,115 Ordinary Shares were issued upon the vesting of 1,525 RSUs granted under the Xero Limited USA Incentive Scheme (**US Scheme**) as part of the remuneration package of certain current and former employees based in the United States. The RSUs vested subject to the terms of the US Scheme.

(iii) 10,000 Ordinary Shares were issued on exercise of vested Options.

(b) 377,925 RSUs have been granted pursuant to the US Scheme and the Xero Limited Restricted Stock Unit and Option Plan (**RSU & Option Plan**) as part of the remuneration package of employees based in New Zealand, the United States, Singapore, South Africa, Canada, Hong Kong and the United Kingdom. The number of RSUs granted was calculated based on the total dollar entitlement of all eligible employees divided by \$62.86, being the 20 day volume weighted average price of Ordinary Shares on ASX (**VWAP**) through to 30 July 2019. The RSUs will vest in varying percentages over the period from 31 July 2019 to 31 March 2022, subject to the terms of the US Scheme and the RSU & Option Plan, as applicable, including the continued employment of the relevant employee with the Xero Limited Group on each vesting date.

(c) 202,500 Options have been granted under the US Scheme and the RSU & Option Plan as remuneration and incentive for certain key employees based in New Zealand, Canada and the

+ See chapter 19 for defined terms.

United States. 150,000 Options will vest in equal percentages over a period of four years, with a final exercise date that is five years from the date of grant, and the remaining 52,500 Options will vest in equal percentages over a period of three years, with a final exercise date of 28 June 2024, subject in each case to the continued employment of the respective key employee with the Xero Limited Group on each vesting date.

4 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

If the additional +securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

- (a) Yes
(b) & (c) N/A, but the Ordinary Shares issued on vesting of RSUs or the exercise of Options (as applicable) will rank equally with the Ordinary Shares then on issue.

5 Issue price or consideration

- (a) (i) \$62.86 per Ordinary Share, being the 20 day VWAP through to 30 July 2019.
- (ii) 1,115 Ordinary Shares were issued upon the vesting of 1,525 RSUs granted under the US Scheme as part of the remuneration package of certain current and former employees based in the United States. 410 RSUs were cancelled in connection with income tax withholding for five individuals based in the United States upon vesting of those RSUs. No cash consideration was required to be paid for these RSUs to vest.
- (iii) 10,000 Options exercised at NZ\$25.75 each.
- (b) RSUs were granted at a value of \$62.86 each, being the 20 day VWAP through to 30 July 2019. No cash consideration is required to be paid for the RSUs to vest.
- (c) N/A. Grant of 202,500 Options pursuant to the US Scheme and the RSU & Option Plan, as remuneration for certain key employees based in New Zealand, Canada and the United States. The exercise price is \$62.86 per Option (being the 20 day VWAP through to 30 July 2019).

+ See chapter 19 for defined terms.

<p>6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<p>(a) (i) Issue of 66,823 Ordinary Shares under the Share Plan as part of the remuneration packages of employees based in Australia and the United Kingdom.</p> <p>(ii) 1,115 Ordinary Shares were issued upon the vesting of 1,525 RSUs granted under the US Scheme as part of the remuneration package of certain current and former employees based in the United States.</p> <p>(iii) Exercise of vested Options previously granted under the RSU & Option Plan to a key individual based in New Zealand.</p> <p>(b) Grant of RSUs pursuant to the US Scheme and the RSU & Option Plan as part of the remuneration package of certain employees based in New Zealand, the United States, Singapore, South Africa, Canada, Hong Kong and the United Kingdom.</p> <p>(c) Grant of Options under the US Scheme and the RSU & Option Plan as remuneration and incentive for certain key employees based in New Zealand, Canada and the United States.</p>
<p>6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?</p> <p>If Yes, complete sections 6b – 6h <i>in relation to the *securities the subject of this Appendix 3B</i>, and comply with section 6i</p>	<p>N/A</p>
<p>6b The date the security holder resolution under rule 7.1A was passed</p>	<p>N/A</p>
<p>6c Number of *securities issued without security holder approval under rule 7.1</p>	<p>N/A</p>
<p>6d Number of *securities issued with security holder approval under rule 7.1A</p>	<p>N/A</p>

6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A						
6f	Number of +securities issued under an exception in rule 7.2	N/A						
6g	If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	N/A						
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A						
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A						
7	<p>+Issue dates</p> <p>Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.</p> <p>Cross reference: item 33 of Appendix 3B.(a)</p>	<p>(a) 31 July 2019</p> <p>(b) 31 July 2019 (grant date)</p> <p>(c) 31 July 2019 (grant date)</p>						
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	<table border="1"> <thead> <tr> <th data-bbox="710 1478 1005 1512">Number</th> <th data-bbox="1013 1478 1316 1512">+Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="710 1512 1005 1736">141,261,302</td> <td data-bbox="1013 1512 1316 1736">Ordinary Shares</td> </tr> <tr> <th data-bbox="710 1736 1005 1769">Number</th> <th data-bbox="1013 1736 1316 1769">+Class</th> </tr> </tbody> </table>	Number	+Class	141,261,302	Ordinary Shares	Number	+Class
Number	+Class							
141,261,302	Ordinary Shares							
Number	+Class							

+ See chapter 19 for defined terms.

9	Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)	575,242	RSUs (a conditional contractual right to be issued Ordinary Shares on a 1:1 basis) outstanding, taking into account all forfeited RSUs to date and the grant of RSUs and the vesting of RSUs as set out in this Appendix 3B
		3,207,631	Unlisted options (convertible into Ordinary Shares on a 1:1 basis) outstanding, taking into account all forfeited options to date and the grant of Options and the exercise of Options as set out in this Appendix 3B
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	(a) As for all Ordinary Shares (b) N/A (c) N/A	

Part 2 - Pro rata issue

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the +securities will be offered	
14	+Class of +securities to which the offer relates	
15	+Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	

18	Names of countries in which the entity has security holders who will not be sent new offer documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	

+ See chapter 19 for defined terms.

-
- 30 How do security holders sell their entitlements *in full* through a broker?
- 31 How do security holders sell *part* of their entitlements through a broker and accept for the balance?
- 32 How do security holders dispose of their entitlements (except by sale through a broker)?
- 33 *Issue date

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of *securities
(tick one)
- (a) (in respect of the "Ordinary Shares" described in Part 1 only, i.e. referenced throughout in paragraph "(a)")
- (b) All other *securities
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

- 35 If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
- 36 If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories
 1 - 1,000
 1,001 - 5,000
 5,001 - 10,000
 10,001 - 100,000
 100,001 and over
- 37 A copy of any trust deed for the additional *securities

Entities that have ticked box 34(b)

38	Number of +securities for which +quotation is sought					
39	+Class of +securities for which quotation is sought					
40	<p>Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?</p> <p>If the additional +securities do not rank equally, please state:</p> <ul style="list-style-type: none"> • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 					
41	<p>Reason for request for quotation now</p> <p>Example: In the case of restricted securities, end of restriction period</p> <p>(if issued upon conversion of another +security, clearly identify that other +security)</p>					
42	Number and +class of all +securities quoted on ASX (<i>including</i> the +securities in clause 38)	<table border="1"> <thead> <tr> <th data-bbox="726 1496 1029 1525">Number</th> <th data-bbox="1029 1496 1323 1525">+Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="726 1525 1029 1736"></td> <td data-bbox="1029 1525 1323 1736"></td> </tr> </tbody> </table>	Number	+Class		
Number	+Class					

+ See chapter 19 for defined terms.

Quotation agreement

1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.



Sign here: Date: 1 August 2019
(Company Secretary)

Print name: Chaman Sidhu

+ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital	
<i>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</i>	
<i>Insert</i> number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	
<i>Add</i> the following: <ul style="list-style-type: none"> • Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 • Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval • Number of partly paid +ordinary securities that became fully paid in that 12 month period <p><i>Note:</i></p> <ul style="list-style-type: none"> • <i>Include only ordinary securities here – other classes of equity securities cannot be added</i> • <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	
<i>Subtract</i> the number of fully paid +ordinary securities cancelled during that 12 month period	
“A”	

+ See chapter 19 for defined terms.

Step 2: Calculate 15% of “A”	
“B”	0.15 <i>[Note: this value cannot be changed]</i>
Multiply “A” by 0.15	
Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used	
<p>Insert number of +equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> • Under an exception in rule 7.2 • Under rule 7.1A • With security holder approval under rule 7.1 or rule 7.4 <p>Note:</p> <ul style="list-style-type: none"> • <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i> • <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	
“C”	
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1	
“A” x 0.15 <i>Note: number must be same as shown in Step 2</i>	
Subtract “C” <i>Note: number must be same as shown in Step 3</i>	
Total [“A” x 0.15] – “C”	<i>[Note: this is the remaining placement capacity under rule 7.1]</i>

+ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
“A” <i>Note: number must be same as shown in Step 1 of Part 1</i>	
Step 2: Calculate 10% of “A”	
“D”	0.10 <i>Note: this value cannot be changed</i>
Multiply “A” by 0.10	
Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used	
Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A <i>Notes:</i> <ul style="list-style-type: none"> • <i>This applies to equity securities – not just ordinary securities</i> • <i>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	
“E”	

+ See chapter 19 for defined terms.

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A	
<p>“A” x 0.10</p> <p><i>Note: number must be same as shown in Step 2</i></p>	
<p>Subtract “E”</p> <p><i>Note: number must be same as shown in Step 3</i></p>	
<p>Total [“A” x 0.10] – “E”</p>	<p><i>Note: this is the remaining placement capacity under rule 7.1A</i></p>

+ See chapter 19 for defined terms.